Does Kiniksa Pharmaceuticals International, plc have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Kiniksa Pharmaceuticals International, plc (KNSA) 55.0 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 96, returns on capital 4, balance-sheet safety 100, capital discipline 24.

Is KNSA stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $2.29 per share versus a recent price of $63.95 — 2690% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has KNSA's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 55.0 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Kiniksa Pharmaceuticals International, plc

KNSA · Healthcare · $5.1B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power96

Median gross margin 87.6% over 5y, very stable.

Returns on capital4

Median ROIC -27.7%, above the 9% hurdle in 13% of years.

Balance-sheet safety100

Net cash position — no leverage risk.

Capital discipline24

Owner earnings trend unclear, share count growing (dilution).

Margin of safety

Above valueOn sale

2690% above value

Owner earnings (normalized): $16.3M
Est. intrinsic value / share: $2.29
Recent price: $63.95
Discount to value: 2690% above value

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

10 years of fundamentals

The business, in plain English

Kiniksa Pharmaceuticals International, plc booked $677.6M of revenue in FY2025 in the Healthcare sector and kept 88.5% of it as gross profit — a high-margin business by that measure. After every other cost, 8.7% of each revenue dollar reached the bottom line.

It earned 12.8% on invested capital in FY2025, with a median of −27.7% across 8 filed years. The Returns on Capital filter above scores it 4/100.

KNSA's filings don't disclose total debt in a form the methodology can use, so leverage is treated as unmeasured — never assumed to be zero.

The share count rose 46.1% between FY2019 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.

Put together: Balance-Sheet Safety is the strongest of the four filters (100/100) and Returns on Capital the weakest (4/100), which is how KNSA lands at 55/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$677.6M FY2025

Gross marginRevenue kept after cost of goods88.5% FY2025

Return on invested capitalOperating profit on the capital employed12.8% FY2025

Owner earningsCash an owner could take out$59.0M FY2025

Gaps in a line mean that item isn’t in KNSA’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale55.0 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — KNSA has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#97 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#95PLX PROTALIX BIOTHERAPEUTICS, INC.55.7 out of 100, Shallow moatShallow moat
#96RIGL RIGEL PHARMACEUTICALS INC55.2 out of 100, Shallow moatShallow moat
#98PTCT PTC Therapeutics, Inc.54.8 out of 100, Shallow moatShallow moat
#99FTV Fortive Corp54.7 out of 100, Shallow moatShallow moat

Compare KNSA with its nearest peers →All Healthcare companies on the Index →

Common questions about KNSA

Does Kiniksa Pharmaceuticals International, plc have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Kiniksa Pharmaceuticals International, plc (KNSA) 55.0 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 96, returns on capital 4, balance-sheet safety 100, capital discipline 24.
Is KNSA stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $2.29 per share versus a recent price of $63.95 — 2690% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has KNSA's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 55.0 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows KNSA’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/KNSA"
  width="340" height="150" style="border:0"
  title="KNSA Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell KNSA. See the disclaimer.